Insulet CORP 8-K filings

Insulet Corporation announced robust second-quarter 2026 financial results, with revenue reaching $801.7 million, a 23.5% increase year-over-year, exceeding the high end of its guidance.

Insulet Corporation has appointed former IDEXX Laboratories CEO Jonathan J. Mazelsky as an independent director effective July 1, 2026.

Insulet Corporation is initiating a voluntary medical device correction for specific lots of Omnipod products due to a manufacturing issue that could lead to insulin under-delivery.

Insulet Corporation announced robust first-quarter 2026 financial results, exceeding revenue guidance and raising its full-year outlook, driven by strong Omnipod sales and strategic product launches.

Insulet Corporation initiated a voluntary medical device correction for specific Omnipod 5 Pods due to a manufacturing issue, expecting up to $40 million in related costs.

Insulet Corporation has formalized the severance agreement with former Chief Financial Officer Ana M. Chadwick, aligning with previously disclosed terms.

Insulet Corporation filed an amended 8-K to confirm Grant Thornton's audit completion and its dismissal, with PricewaterhouseCoopers taking over as the independent auditor for fiscal year 2026.

Insulet Corporation has extended and amended its material purchase agreement with NXP USA, Inc., covering product pricing, volume, and order flexibility through 2026.

Insulet Corporation announced the appointment of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026, replacing Grant Thornton LLP.

Insulet Corporation has amended and restated its Annual Incentive Plan, effective January 1, 2026, to clarify termination definitions, expand eligibility for prorated awards upon retirement, and augment compensation recoupment language.

Insulet Corporation reported strong third-quarter 2025 financial results, with revenue up 29.9% to $706.3 million, and raised its full-year 2025 revenue and margin guidance.

Insulet Corporation announced the appointment of Robbie Huffines, former Global Chair of Investment Banking at JP Morgan Chase & Co., to its Board of Directors, effective October 31, 2025.

Insulet Corporation announced the appointment of Flavia H. Pease as its new CFO, effective September 30, 2025, and expects to exceed its third-quarter 2025 revenue growth guidance.

Insulet Corporation reported a 32.9% year-over-year revenue increase in Q2 2025, exceeding guidance, and subsequently raised its full-year revenue and adjusted operating margin guidance.

Insulet Corporation announced the refinancing of its credit agreement with new term loans at reduced interest rates and the full redemption of its 0.375% Convertible Senior Notes due 2026.

Insulet Corporation's shareholders overwhelmingly approved the new 2025 Stock Option and Incentive Plan, authorizing up to 7.4 million shares for equity awards, and re-elected all Class III director nominees at their annual meeting.

Insulet Corporation announced a 29% year-over-year revenue increase for Q1 2025 and raised its full-year revenue and gross margin guidance.

Insulet Corporation announces the appointment of Ashley McEvoy as President and CEO, succeeding Jim Hollingshead, and anticipates exceeding its first quarter revenue guidance while planning to increase its full-year forecast.

Insulet Corporation has entered into a consulting agreement with its former Senior Vice President and Chief Technology Officer, Mark Field, following his departure from the company.

Insulet Corporation finalized a $450 million senior notes offering and amended its credit agreement to extend the maturity of revolving credit commitments and increase the amount of revolving credit commitments.

Insulet Corporation announces the pricing of a $450 million private placement of senior unsecured notes due 2033 to refinance existing convertible senior notes and for general corporate purposes.

Insulet Corporation plans to offer $450 million in senior unsecured notes and amend its credit agreement to extend maturity and increase revolving credit commitments.

Mark Field, Senior Vice President and Chief Technology Officer of Insulet Corporation, has left the company, with Amit Guliani appointed as acting CTO.

Insulet Corporation and NXP USA, Inc. have amended their purchase agreement, extending it through 2025 with updated terms on pricing, volume, warranties, and product modifications.

Insulet Corporation's Talent and Compensation Committee approved revisions to the company's equity agreements, including stock option, restricted stock unit, and performance stock unit agreements, to enhance compensation recoupment language and update international tax and securities law compliance provisions.

Insulet Corporation announces a 22% increase in full-year 2024 revenue, exceeding $2 billion for the first time, driven by strong demand for its Omnipod insulin delivery system.

Insulet Corporation secured a $452 million jury verdict against EOFlow Co., Ltd. for misappropriating trade secrets related to its insulin pump technology.

Insulet Corporation announced a 26% year-over-year revenue increase for the third quarter of 2024, driven by strong Omnipod sales and the recent FDA clearance for type 2 diabetes.

Insulet Corporation announced a 23% year-over-year revenue increase for the second quarter of 2024, exceeding expectations and leading to raised full-year guidance.

Insulet Corporation has successfully refinanced its existing term loans, extending the maturity date to August 2, 2031, and reducing interest rate margins on both term and revolving loans.